Péter Döme1,2, Péter Kunovszki3, Péter Takács3, László Fehér4, Tamás Balázs5, Károly Dede5, Siobhán Mulhern-Haughey6, Sébastien Barbreau7, Zoltán Rihmer1,2. 1. Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary. 2. Nyírő Gyula National Institute of Psychiatry and Addictions, Budapest, Hungary. 3. Janssen Global Commercial Strategy Organization, Budapest, Hungary. 4. Janssen-Cilag Ltd, Budapest, Hungary. 5. Healthware Ltd, Budapest, Hungary. 6. Janssen EMEA, Dublin, Ireland. 7. Janssen EMEA, Issy-les-Molineaux, France.
Abstract
PURPOSE: Treatment-resistant depression (TRD) is associated with a poor quality of life and high economic burden. This observational retrospective epidemiological study aimed to estimate the proportion of patients with TRD within a cohort of patients with major depressive disorder (MDD) in Hungary and examine the mortality and comorbidities of patients with and without TRD. PATIENTS AND METHODS: This study included patients with MDD who experienced onset of a new depressive episode between 01 January 2009 and 31 August 2015, using data from a nationwide, longitudinal database. RESULTS: Overall, 99,531 patients were included in the MDD cohort, of which 8,268 (8.3%) also met the criteria for TRD. The overall survival of non-TRD patients was longer than in TRD patients; the risk of mortality for TRD patients was significantly higher than of non-TRD patients (HR [CI] 1.381 [1.212-1.571]; p<0.001). Patients with TRD had a significantly higher probability of having "Neurotic, stress-related and somatoform disordersˮ, autoimmune conditions, cardio- or cerebrovascular diseases, thyroid gland diseases and self-harming behaviour not resulting in death than non-TRD patients (for all comparisons, p values were less than 0.005). DISCUSSION: To our best knowledge, this is the first study to assess the frequency of TRD in Hungary. In a cohort of Hungarian MDD patients, we have found that the proportion of TRD (~8.3%) is comparable to those reported in previous studies with similar methodology from other countries. The majority of our other main findings (e.g. more frequent self-harming behaviour, increased risk of "Neurotic, stress-related and somatoform disordersˮ and higher overall mortality in TRD subjects) are also in line with previous results from other countries. Taking the substantial proportion of patients with TRD into consideration, a more comprehensive and targeted treatment strategy would be required for these individuals.
PURPOSE: Treatment-resistant depression (TRD) is associated with a poor quality of life and high economic burden. This observational retrospective epidemiological study aimed to estimate the proportion of patients with TRD within a cohort of patients with major depressive disorder (MDD) in Hungary and examine the mortality and comorbidities of patients with and without TRD. PATIENTS AND METHODS: This study included patients with MDD who experienced onset of a new depressive episode between 01 January 2009 and 31 August 2015, using data from a nationwide, longitudinal database. RESULTS: Overall, 99,531 patients were included in the MDD cohort, of which 8,268 (8.3%) also met the criteria for TRD. The overall survival of non-TRD patients was longer than in TRD patients; the risk of mortality for TRD patients was significantly higher than of non-TRD patients (HR [CI] 1.381 [1.212-1.571]; p<0.001). Patients with TRD had a significantly higher probability of having "Neurotic, stress-related and somatoform disordersˮ, autoimmune conditions, cardio- or cerebrovascular diseases, thyroid gland diseases and self-harming behaviour not resulting in death than non-TRD patients (for all comparisons, p values were less than 0.005). DISCUSSION: To our best knowledge, this is the first study to assess the frequency of TRD in Hungary. In a cohort of Hungarian MDDpatients, we have found that the proportion of TRD (~8.3%) is comparable to those reported in previous studies with similar methodology from other countries. The majority of our other main findings (e.g. more frequent self-harming behaviour, increased risk of "Neurotic, stress-related and somatoform disordersˮ and higher overall mortality in TRD subjects) are also in line with previous results from other countries. Taking the substantial proportion of patients with TRD into consideration, a more comprehensive and targeted treatment strategy would be required for these individuals.
Authors: Parashar Koirala; Bo Hu; Murat Altinay; Manshi Li; Amy L DiVita; Kelly A Bryant; Harish S Karne; Jess G Fiedorowicz; Amit Anand Journal: J Psychiatr Res Date: 2018-12-08 Impact factor: 4.791
Authors: Lucie Bartova; Markus Dold; Alexander Kautzky; Chiara Fabbri; Marie Spies; Alessandro Serretti; Daniel Souery; Julien Mendlewicz; Joseph Zohar; Stuart Montgomery; Alexandra Schosser; Siegfried Kasper Journal: World J Biol Psychiatry Date: 2019-07-25 Impact factor: 4.132
Authors: Margherita Barbuti; Lorenzo Mazzarini; Eduard Vieta; Jean-Michel Azorin; Jules Angst; Charles L Bowden; Sergey Mosolov; Allan H Young; Giulio Perugi Journal: J Affect Disord Date: 2019-06-04 Impact factor: 4.839
Authors: M Soledad Cepeda; Jenna Reps; Daniel Fife; Clair Blacketer; Paul Stang; Patrick Ryan Journal: Depress Anxiety Date: 2017-12-15 Impact factor: 6.505
Authors: Antal Zemplényi; Judit Józwiak-Hagymásy; Sándor Kovács; Dalma Erdősi; Imre Boncz; Tamás Tényi; Péter Osváth; Viktor Voros Journal: BMC Psychiatry Date: 2022-06-28 Impact factor: 4.144